Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
14 août 2024 08h30 HE
|
Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
17 juil. 2024 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
06 juin 2024 08h30 HE
|
Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
15 mai 2024 18h00 HE
|
Vaccinex, Inc.
Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
07 févr. 2024 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
03 janv. 2024 09h46 HE
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 08h00 HE
|
Vaccinex, Inc.
Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...
Vaccinex, Inc. Announces Reverse Stock Split
22 sept. 2023 16h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 mai 2023 16h45 HE
|
Vaccinex, Inc.
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
25 avr. 2023 08h00 HE
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....